| Literature DB >> 32801693 |
Omnia Hesham Abdelhafez1, Taha Farouk Shehata Ali2, John Refaat Fahim3, Samar Yehia Desoukey3, Safwat Ahmed4, Fathy A Behery5,6, Mohamed Salah Kamel3, Tobias A M Gulder7, Usama Ramadan Abdelmohsen1,3.
Abstract
BACKGROUND: Soft corals have been endorsed as a plentiful source of bioactive compounds with promising anti-inflammatory activities; therefore, exploring their potential as source of anti-inflammatory metabolites has stimulated a growing research interest.Entities:
Keywords: Nephthea; anti-inflammatory; metabolomics; molecular docking; nanoparticles; soft coral
Mesh:
Substances:
Year: 2020 PMID: 32801693 PMCID: PMC7395700 DOI: 10.2147/IJN.S239513
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1TEM photos of the formed silver nanoparticles of the petroleum ether (A) and ethyl acetate (B) fractions of Nephthea sp.
Figure 2UV–Vis spectra after synthesis of nanoparticles using the petroleum ether (A) and ethyl acetate (B) fractions of Nephthea sp.
Figure 3FTIR spectra after synthesis of nanoparticles using the petroleum ether (A) and ethyl acetate (B) fractions of Nephthea sp.
Figure 4Dynamic light scattering analysis of synthesized SNPs (A) Pet. ether nano extract, (B) ethyl acetate nano extract.
Figure 5Chemical structures of the dereplicated metabolites from Nephthea sp. (Stereochemistry was shown as predicted from MarinLit).
In vitro COX-1 and COX-2 Inhibitory Activities of the Crude Extract and Different Fractions of Nephthea Sp., Along with Their Selectivity Ratio
| Extract/Fraction | COX-1 (IC50 in µg/mL) | ((COX-2 (IC50 in µg/mL) | Selectivity Ratio |
|---|---|---|---|
| Total extract | 33.72 | 46.75 | 1.38 |
| Petroleum ether fraction | 381.96 | 27.43 | 0.07 |
| Ethyl acetate fraction | 100.51 | 141.20 | 1.40 |
| n-Butanol fraction | 254.66 | 39.33 | 0.15 |
| Acetone fraction | 399.69 | 36.15 | 0.09 |
| Petroleum ether nano fraction | 494.20 ± 16.34 | 3.34 ± 0.19 | 147.96 |
| Ethyl acetate nano fraction | 714.47 ± 22.59 | 4.53 ± 0.24 | 157.71 |
| AgNO3 | 249.86 ± 9.26 | 4.38 ± 0.26 | 57.04 |
| Celecoxib | 119.97 | 5.63 | 0.04 |
| Indomethacin | 127.57 | 52.24 | 0.40 |
Figure 6In-vitro anti-COX-1 potential of the tested samples.
Figure 7In-vitro anti-COX-2 potential of the tested samples.
Figure 83D and 2D plots of the poses of Mofezolac in the binding pocket of COX-1.
Figure 123D and 2D plots of the poses of compound 9 in the binding pocket of COX-1.
Figure 133D and 2D plots of the poses of Rofexocib in the binding pocket of COX-2.
Figure 173D and 2D plots of the poses of Sinularioperoxide E in the binding pocket of COX-2.